Conference Roundup

Maralixibat proves effective for young adults with Alagille syndrome transitioning to adult care

Maralixibat (MRX) has proven to be an effective, durable, and well-tolerated treatment for individuals aged 16 years and older with Alagille syndrome (ALGS), according to data presented at NASPGHAN 2023. This study, which included both young adults transitioning to adult care and adults initiating treatment, demonstrated significant improvements in pruritus...